Reported Saturday, Genmab Reports Rina-S Showed 45.9% ORR, 9.5-Month mPFS And 12.1-Month mDOR In Platinum-Resistant Ovarian Cancer, With Activity Regardless Of FRα Expression Levels

Benzinga

2026.10.05 06:56 (GMT+0)

Abrir en Benzinga